Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future

Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).

(2020) Richard Cathomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.

(2020) Shilpa Gupta et al.   JOURNAL OF CLINICAL ONCOLOGY

IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

(2020) Maha H. A. Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).

(2020) Nick Van Dijk et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.

(2020) Christopher J. Hoimes et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.

(2020) Hristos Z. Kaimakliotis et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

(2020) Matthew D Galsky et al.   LANCET

Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy

(2020) Jeffrey J. Leow et al.   EUROPEAN UROLOGY

Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

(2020) Peter Boxley et al.   Bladder Cancer

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

(2020) Thomas Powles et al.   LANCET ONCOLOGY

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

(2020) Nick van Dijk et al.   NATURE MEDICINE

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

(2020) Jianjun Gao et al.   NATURE MEDICINE

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

(2020) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in Bladder Cancer

(2019) Venu Madhav Konala et al.   AMERICAN JOURNAL OF THERAPEUTICS

The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review

(2019) Luca Mazzarella et al.   EUROPEAN JOURNAL OF CANCER

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update

(2019) Marko Babjuk et al.   EUROPEAN UROLOGY

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies

(2019) Andrea Necchi et al.   EUROPEAN UROLOGY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

(2018) Patrick Danaher et al.   Journal for ImmunoTherapy of Cancer

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

(2018) A. Gordon Robertson et al.   CELL

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

(2018) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

Bladder Cancer Survivorship

(2018) Sumeet K. Bhanvadia   Current Urology Reports

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

(2017) Marko Babjuk et al.   EUROPEAN UROLOGY

The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives

(2017) Hampig Raphael Kourie et al.   Immunotherapy

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

(2017) Andrea B. Apolo et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

(2017) Arjun V Balar et al.   LANCET ONCOLOGY

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment 1 1MPS is an investor in and consultant for Urogen. SAP is consultant and advisor for Vaccinex. The remaining authors have nothing to disclose.

(2017) Tian C. Zhou et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

(2016) Sam S. Chang et al.   JOURNAL OF UROLOGY

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis

(2016) Ming Yin et al.   ONCOLOGIST

CUA guidelines on the management of non-muscle invasive bladder cancer

(2015) Wassim Kassouf et al.   CUAJ-Canadian Urological Association Journal

Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity

(2014) Elizabeth R. Plimack et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

(2014) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Increasing Utilization of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer in the United States

(2014) Kirk A. Keegan et al.   Current Urology Reports

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013

(2013) Marko Babjuk et al.   EUROPEAN UROLOGY

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder

(2012) Georgios Gakis et al.   EUROPEAN UROLOGY

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

(2011)   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

(2009) Richard J. Sylvester et al.   EUROPEAN UROLOGY

Long-term Results of Selective Partial Cystectomy for Invasive Urothelial Bladder Carcinoma

(2008) Marc C. Smaldone et al.   UROLOGY